2009 Medical Innovation Summit
Sam PalmisanoCEO, IBM
David BrennanCEO, AstraZeneca
Fred HassanCEO, Schering-Plough
Kári Stefánsson, MDCEO, deCODE genetics
David EpsteinCEO, Oncology & Molecular Diagnostics, Novartis
Greg LucierCEO, Life Technologies
Wayne Rosenkrans, Jr., PhDCEO, Personalized Medicine Coalition
Euan Thomson PhDCEO, Accuray, Inc.
David BrooksNew York Times
Edward McCabe, MD, PhDAmerican Society of Human Genomics
William Hait, MD, PhDOrtho Oncology Research & Development
Richard Gaynor, MDLilly
Richard Schilsky, MDImmediate Past President, American Society of Clinical Oncology
Anne WojcickiCo-Founder, 23 and Me
Dietrich Stephan, PhDNavigenics
Eric ZieboldMandarin Oriental
Edward BuckleyBiotechnology Industry Organization
Roger LongmanPharma, Elsevier Business Intelligence
Steve SchimolerCrop, Bistro & Bar
Beth Seidenberg, MDKleiner Perkins Caufield & Byers
Margaret Hamburg, MDFDA Commissioner
Dan Vasella, MDCEO, Novartis
Richard ClarkCEO, Merck
Sol Barer, PhDCEO, Celgene
Thomas Miller, Jr.CEO, Workflow & Solutions Division, Siemens Healthcare
Tomas PuuseppCEO, Elekta
Harry ReinFoundation Medical Partners
Darren CarrollVP, New Ventures Division, Lilly
Roy DavisJohnson & Johnson Development Corp.
Mark VachonPresident & CEO, Americas, GE Healthcare
Sir Bruce Ponder, MD, PhDCancer Research UK Cambridge Research Institute
Jon Wigginton, MDBristol Myers Squibb, Inc.
James Doroshow, MDNCI
Nancy Simonian, MDMillennium: The Takeda Oncology Co.
Dow WilsonVarian Medical Systems
Mark TrusheimCo-Bio Consulting
Richard Scheller, PhDGenentech Research and Early Development
Randy ScottCEO, Genomic Health
David Ewing DuncanBest-Selling Author and Science Journalist
Debra LappinCouncil for American Medical Innovation
Jean-Marc Andral, IBA
Jean-Marc Andral is Particle Therapy President for IBA (Ion Beam Applications) since April 2007. Prior to joining IBA, he worked for General Electric Medical Systems where he held various managing functions from 1985 as Project Manager After Sale, rising to General Manager indirect distribution Operations, Vice-President Web developments and General Manager Middle East and Africa.
Mr. Andral graduated from Ecole Centrale de Paris in 1971 asan engineer in arts and Manufactures and has a MBA of INSEAD in Fontainebleau.
Mr. Andral received the President's award of GE in 2005.
Back to Top
Sol Barer, PhD, Celgene
Dr. Barer has been Chief Executive Officer of Celgene since May 2006 and Chairman since January 2007. He was appointed President in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors. He previously served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and the Vice President, Technology, from September 1987 to October 1990.
Dr Barer joined the Celanese Research Company in 1974 and formed the Biotechnology group that was subsequently spun out to form Celgene.
Dr. Barer holds numerous awards including the "Dream & Promise Award" (Children's Brain Tumor Foundation) "Odyssey Award" (Center for Medicine in the Public Interest), the "Corporate Vision Award" (Gilda's Club), the "Sparkle of Hope Award" (Community Hope), "Master Entrepreneur Award" (Ernst & Young), "The Hall of Distinguished Alumni Award" (Rutgers University Alumni Federation), "Dr. Sol J. Barer Award for Vision, Innovation and Leadership" (BioNJ), "Science and Technology Industry Medal" (R&D Council of NJ), "Rutgers University Graduate School Annual Distinguished Alumnus Award", "Winthrop-Sears Medal" (The Chemists Club and the Chemical Heritage Foundation), and "Albert Einstein Award in Life Sciences" (Global Capital Associates and Jerusalem Fund, Israel), "DART/NYU Biotechnology Achievement Award in Applied Biotechnology" (Biotechnology Study Center of the New York University School of Medicine).
Dr. Barer is also is on the Board of Directors of Amicus Therapeutics, serves on the Board of Trustees of BioNJ and is on the Board of the Brooklyn College Foundation and on the Board of Trustees of Rutgers - The State University of New Jersey. He has previously served as a Commissioner of the New Jersey Commission on Science and Technology.
Dr. Barer received a PhD in Organic Chemistry from Rutgers University and BS from Brooklyn College.
Back to Top
Maria Bartiromo, CNBC
Maria Bartiromo is the anchor of CNBC's "Closing Bell with Maria Bartiromo," and host and managing editor of the nationally syndicated business, financial and economic news program, "Wall Street Journal Report with Maria Bartiromo," which was recently rated the most watched financial news program in America. It appears on over 200 stations weekly and provides the clarity, depth and insight of The Wall Street Journal in a television magazine format. She contributes to NBC's Today Show, Today In L.A., Today in Chicago and CNBC Asia's daily broadcasts.
Ms. Bartiromo joined CNBC in 1993 after five years as a producer and assignment editor with CNN Business News. In 1995, Ms. Bartiromo became the first journalist to report live from the New York Stock Exchange on a daily basis for Squawk Box. She reported from the NYSE for 10 years.
In May 2008, Ms. Bartiromo received a Gracie Award in the category of Outstanding Documentary for her documentary "Greenspan: Power, Money & the American Dream."
Ms. Bartiromo writes a weekly column in BusinessWeek, "FaceTime with Maria Bartiromo," as well as a weekly column in Milano Finanza. Ms. Bartiromo writes a weekly column in BusinessWeek, "FaceTime with Maria Bartiromo," as well as a weekly column in Milano Finanza.
In addition to being a member of the Board of Trustees of New York University, Bartiromo is on the Board of Directors of the New York City Ballet, the Girl Scout Council of Greater New York; as well as PENCIL, Public Education Needs Civic Involvement and Leadership, which is a non profit group focusing on improving New York high schools. She also is a Young Global Leader of the World Economic Forum, a member of The Wharton Leadership Advisory Board and a member of the Columbus Citizens Foundation.
Ms. Bartiromo graduated from New York University, where she majored in journalism and minored in economics.
Back to Top
David Brennan, AstraZeneca
David Brennan was appointed Chief Executive Officer of AstraZeneca effective 1 January 2006 and is now based at the global headquarters in London. From 2001 until his appointment to CEO, David was President and Chief Executive Officer of AstraZeneca LP, the Company's North American subsidiary for the U.S. and Canada. He was appointed Executive Board Director of AstraZeneca in 2005.
David began his career in 1975 at Merck, where he started as a sales representative in the U.S. Division and later worked in sales and marketing management in the US and International divisions. He joined AstraMerck in 1992 and helped to build the joint venture into a multi-billion dollar business in the U.S. which was then merged to form AstraZeneca in 1999.
He is an alumnus of Gettysburg College where he studied Business Administration.
In addition to his role as Executive Director of AstraZeneca PLC he is also:
- Chairman-elect of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Member of the Executive Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Member of the European Roundtable of Industrialists
- Member of the National Institute of Health Roundtable on Evidence Based Medicine
- Commissioner of the UK Commission for Employment and Skills
- Past Chairman of the Board of the Southeastern Pennsylvania Chapter of the American Heart Association
- Honorary Board member of the US CEO Roundtable on Cancer
David Brooks, New York Times
David Brooks has a gift for bringing audiences face to face with the spirit of our times with humor, insight and quiet passion. He is a keen observer of the American way of life and a savvy analyst of present-day politics and foreign affairs.
Author of two books of what he calls "comic sociology"- descriptions of how we live and "the water we swim in" that are as witty and entertaining as they are revealing and insightful: Bobos in Paradise and On Paradise Drive. Bobos in Paradise was a New York Times bestseller.
David Brooks has worked at The Weekly Standard, joining the magazine at its inception and serving as senior editor.
He has been a contributing editor at Newsweek and the Atlantic Monthly. He worked at The Wall Street Journal for nine
years in a range of positions, including op-ed editor. He has written for The New Yorker, The New York Times Magazine,
Forbes, The Washington Post and many other periodicals.
Back to Top
Edward Buckley, Biotechnology Industry Organization
Edward (Ted) Buckley joined the Biotechnology Industry Organization (BIO) as the Director of Economic Policy in August 2006. In this role, Dr. Buckley is responsible for examining the economic impact of policy proposals on the biotechnology industry. In addition he conducts and commissions analyses that support the creation of an environment where innovation can thrive.
Dr. Buckley previously worked as a consultant at McKinsey and Company where he advised a variety of companies including health insurance and pharmaceutical companies.
Prior to joining McKinsey and Company, Dr. Buckley was the first National Center for Health Statistics (NCHS)/AcademyHealth fellow, where he completed his dissertation research.
Before graduate school, Dr. Buckley worked in a range of fields including IT consulting, operations and logistics management and served as a live-in assistant for mentally handicapped adults in L'Arche communities in both Canada and Germany.
Dr. Buckley received is BA in 1991 in Mathematics from the
University of Pennsylvania, his MA in 2001 and his PhD
in 2004 in Applied Economics from the Wharton School of
Business, University of Pennsylvania.
Back to Top
Darren Carroll, New Ventures Division, Lilly
Mr. Carroll is vice president of the New Ventures division of Eli Lilly and Company, which includes Lilly Ventures and Lilly Asian Ventures, the first venture capital group of its kind in the pharmaceutical industry. Prior to assuming his current role, Mr. Carroll was the founding chief executive officer of InnoCentive, Inc., the first open-innovation business in the physical sciences, which he spun out of Lilly. Among other positions Mr. Carroll has held at Lilly, he was the U.S. attorney for Prozac ®.
Mr. Carroll has also served as senior vice president of RealMed, a venture-backed company based in Indianapolis, which created the first real-time health claims adjudication system. Earlier in his career, he practiced law with a large private law firm in New York and negotiated complex technology transactions for General Electric Company.
His education includes a J.D. degree from Syracuse University College of Law. He also holds a bachelor's from Syracuse University and a masters of public
administration degree from the Maxwell School of Syracuse, where he is a member of the Board of Advisors. He is also a member of the Board of Directors for
Lilly Ventures and Lilly Asian Ventures portfolio companies including Citic Pharmaceuticals, Novast Holdings, Hydra Biosciences, InnoCentive and GlobeImmune,
and is chairman of the advisory board for the Indiana Future Fund.
Back to Top
Richard Clark, Merck & Co., Inc.
Richard T. Clark is the Chairman, President and Chief Executive Officer of Merck & Co., Inc., a global research-driven pharmaceutical company that discovers, develops, manufactures and markets innovative medicines and vaccines. Mr. Clark has been President and CEO of Merck since May 2005, and chairman of the board since April 2007.
Previously Mr. Clark held the position of President of the Merck Manufacturing Division, with responsibility for Merck's global network of manufacturing operations, information services and operational excellence organizations worldwide.
In a career spanning more than 36 years with Merck, Mr. Clark has held a broad range of senior management positions within the company's manufacturing organization. Mr. Clark joined Merck in 1972 as a Quality Control Inspector, and he progressed through a series of increasingly responsible roles in the areas of production, new products planning, industrial engineering and management engineering, becoming Vice President, Materials Management and Management Engineering in 1991.
In 1993, Mr. Clark was appointed Vice President, Procurement and Materials Management. He became Vice President of North American Operations for the Merck Manufacturing Division in 1994 and Senior Vice President in 1996. In 1997, he was appointed Senior Vice President of Quality and Commercial Affairs. Later that year, Mr. Clark joined the Merck-Medco Managed Care subsidiary as Executive Vice President and Chief Operating Officer. He later served as Chairman, President and Chief Executive Officer of the newly named Medco Health Solutions, overseeing plans to prepare that organization to become a publicly traded company. He returned to the Merck Manufacturing Division as President in June 2003.
From 2008 to 2009 he served as board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country's leading pharmaceutical research and biotechnology companies.
Mr. Clark earned his bachelor's degree in Liberal Arts from Washington & Jefferson College, and his M.B.A. from American University. He served as a Lieutenant
in the U.S. Army from 1970 to 1972 before joining Merck.
Back to Top
Roy Davis, Johnson & Johnson Development Corporation
Roy Davis is President, Johnson & Johnson Development Corporation (JJDC) and Vice President, Corporate Development, Johnson & Johnson. He was named to this position in January, 2008. He is responsible for all Acquisition and Licensing in areas outside current J&J business sectors; all Venture Capital investing on behalf of Johnson & Johnson, as well as all J&J Internal Ventures. These efforts are focused on developing new companies for J&J that offer potentially transformational health care solutions. Mr. Davis is a member of the Surgical Care Group.
Mr. Davis joined the Johnson & Johnson Family of Companies in 1984. He moved through line leadership positions of increasing responsibility in the organization in the U.S., Europe and Asia and then to Company Group Chairman for Diagnostics (worldwide) in 2003, before assuming his current role in January, 2008.
He is currently a member of the Industrial Advisory Board of Cleveland Clinic.
Mr. Davis received a Bachelor of Science degree from the State University of New York and a Master of Science degree from Rensselaer Polytechnic Institute.
Back to Top
James Doroshow, MD, NCI
Dr. James H. Doroshow has been the Director of the Division of Cancer Treatment and Diagnosis, National Cancer Institute, since 2004. From 1983 to 2004, Dr. Doroshow was the Chairman of the City of Hope Comprehensive Cancer Center's Department of Medical Oncology and Therapeutics Research. From the time of his first research grant in 1980, Dr. Doroshow was continuously funded by the NCI until he moved to the NIH in 2004. He is the author of over 300 full-length publications in the areas of anthracycline antibiotic molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors. Dr. Doroshow served from 1990-1992 as Chairman of the National Institutes of Health Experimental Therapeutics II Study Section, from 1995-2001 as a member of the Subspecialty Board on Medical Oncology of the American Board of Internal Medicine, from 1999-2000 as Chairman of NCI's Scientific Review Group A-Cancer Centers, and from 2004-2007 as a member of the FDA's Oncologic Drugs Advisory Committee. Dr. Doroshow chaired the NCI's Clinical Trials Working Group from 2004-2005 that developed a comprehensive set of initiatives to restructure the national cancer clinical trials enterprise.
Dr. Doroshow received his bachelor=s degree, magna cum laude, from Harvard College in 1969 and his medical degree alpha omega alpha from Harvard Medical School in 1973.
After completing an internship and residency in Internal Medicine at the Massachusetts General Hospital in Boston, he spent three years (1975-78) performing his fellowship
in Medical Oncology on the Medicine and Clinical Pharmacology Branches of the NCI.
Back to Top
David Ewing Duncan, Best-Selling Author and Science Journalist
David Ewing Duncan is an award-winning, best-selling author of seven books and numerous essays, articles and short stories; and a television, radio and film producer and correspondent. He is a columnist for MIT Technology Review and the Chief Correspondent for public radio's "Biotech Nation". He writes for the New York Times, Fortune, Discover, National Geographic, and many other publications. At UC Berkeley he is the Director of the Center for Life Science Policy and a Visiting Researcher at the Graduate School of Journalism. David's most recent book is the bestselling Experimental Man: What one man's body reveals about his future, your health, and our toxic world (Wiley). His previous book was Masterminds: Genius, DNA and the Quest to Rewrite Life (Harper Perennial). He wrote the international bestseller Calendar: Humanity's Epic Struggle to Determine a True and Accurate Year (Harper-Collins/Avon), published in 19 languages, and a bestseller in 14 countries.
David has been a Contributing Editor and columnist for Conde Nast
Portfolio, and a Contributing Editor for Wired and Discover; he has
been a longtime commentator for NPR's "Morning Edition", and
a special correspondent and producer for ABC's Nightline and
20/20. He has been a correspondent for NOVA's ScienceNow!,
and a producer for Discovery Television. He has written for
Harper's, Atlantic Monthly, Smithsonian, Outside, The Telegraph,
The Guardian, The Washington Post Book World, The San
Francisco Chronicle, and The New York Times, among others.
Back to Top
David Epstein, Oncology & Molecular Diagnostics, Novartis
David Epstein is President and Chief Executive Officer of Novartis Oncology and Novartis Molecular Diagnostics. He is responsible for leading Novartis' global Oncology Business Unit, one of the world's top Oncology companies with seven key marketed products - Glivec, Femara, Zometa, Sandostatin LAR, Exjade, Tasigna and Proleukin - and a leading pipeline recognized as exceptionally broad and deep. For this, Epstein currently oversees a staff of more than 5,000 employees operating in more than 50 countries. In 2007, Novartis Oncology's sales grew 12.5% to $6.9 billion and market share grew to 10.03%.
Additionally, Epstein is responsible for leading Novartis Molecular Diagnostics, a new business launched in December 2008 to recognize the growing role of diagnostics in improving healthcare utilization worldwide. He is a member of Novartis AG's Pharma Committee, a member of the Pharma Executive Committee (PEC) and a member of the Executive Council of Novartis (ECN).
Epstein has held a series of positions of increasing responsibility since joining the company as a new product manager with Sandoz in 1989. Epstein most recently served as Chief Executive Officer, Novartis Specialty Medicines, overseeing the global Ophthalmics and Transplantation & Immunology Business Units in addition to his responsibilities leading Novartis Oncology. He previously served as Chief Operating Officer of Novartis Pharmaceuticals Corporation in the U.S and has held several positions in marketing and general management.
During the planning process that resulted in the 1996 merger of Ciba-Geigy Ltd. and Sandoz Ltd., Epstein co-chaired the U.S. and Canadian Pharma Steering Committees as the Integration Officer, North America. In January 1997, he was promoted to Vice President, Marketing and Sales, Specialty Business Sector, responsible for U.S. business units focused on Oncology and Transplant/Immunology/Tissue Engineering. Prior to joining the company, he was an associate in the Strategy Practice of consulting firm Booz, Allen and Hamilton.
Epstein holds a BS degree in Pharmacy with high honors from
Rutgers University College of Pharmacy and an MBA in Finance
and Marketing from the Columbia University Graduate School
Back to Top
Richard Gaynor, MD, Lilly
Richard Gaynor, MD, joined Eli Lilly and Company as Vice President for Cancer Research and Clinical Investigation in August 2002. Currently he is Vice President of Cancer Research and the Global Oncology Platform.
Gaynor received a bachelor of science degree in biology from Texas Tech University and received a doctor of medicine degree from the University of Texas Southwestern Medical School. He served his internship and residency in internal medicine from at Parkland Memorial Hospital in Dallas, Texas. He completed a fellowship in hematology-oncology at the University of California at Los Angeles (UCLA) School of Medicine and then served on it's faculty. He received board certification in internal medicine, hematology and medical oncology.
Prior to joining Lilly, Gaynor was a Professor of Medicine and Microbiology at the University of Texas Southwestern Medical Center (UTSW) in Dallas and held several important leadership positions. He was Chief of the Division of Hematology and Oncology at UTSW and Director of the Harold C. Simmons Comprehensive Cancer Center there in addition to his work as the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology. He served on numerous NIH advisory committees and was elected to both the American Society of Clinical Investigation and Association of American Physicians.
Gaynor is on the editorial board of several scientific journals
and has an extensive publication record totaling more than 140
scientific articles. He serves on the board of the Damon Runyon
Cancer Research Foundation and the Walther Cancer Institute
and on several committees for the American Association of
Cancer Research and other leading cancer organizations.
Back to Top
Shawn Guse, CPAC and TomoTherapy
Shawn Guse serves as CEO of Compact Particle Acceleration Corporation, which is commercializing a particle therapy system based upon a compact,
novel method of particle acceleration. Mr. Guse also serves as the Vice President of International Operations for TomoTherapy Incorporated.
Previously, Mr. Guse served TomoTherapy as interim Vice President of Global Sales and General Counsel and Corporate Secretary. Prior to joining
TomoTherapy, Mr. Guse was engaged in the private practice of law focusing on high-growth technology companies, structuring and executing corporate sales
and acquisitions, debt and equity financing, technology licensing and transfer, and international distribution and sales. Mr. Guse has a B.A. in
Economics from the University of Wisconsin - Milwaukee and a J.D. from the University of Wisconsin Law School.
Back to Top
William Hait, MD, PhD, Ortho Oncology
Dr. William N. Hait was appointed Senior Vice President, Worldwide Head of Hematology and Oncology for Johnson & Johnson in March 2007. Prior to joining Johnson & Johnson, he was the founding Director of The Cancer Institute of New Jersey and Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School from January 1993 to March 2007. Under Dr. Hait's leadership, The Cancer Institute of New Jersey was successful in obtaining cancer center designation from the National Cancer Institute in 1996 and received the National Cancer Institute's highest designation of Comprehensive Cancer Center in 2002.
After earning his B.A. from the University of Pennsylvania, Dr. Hait received his M.D. and Ph.D. (Pharmacology) cum laude from the Medical College of Pennsylvania, where he was elected to Alpha Omega Alpha. He joined the Yale University School of Medicine faculty in 1984 and was quickly promoted to Associate Professor of Medicine and Pharmacology. Dr. Hait served as Associate Director of the Yale University Comprehensive Cancer Center and Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit at the Yale University School of Medicine. He was appointed Chief of Medical Oncology at the Yale University School of Medicine in 1988. Dr. Hait is Board Certified in Internal Medicine and Medical Oncology.
Dr. Hait served as President of the American Cancer Society, Middlesex Unit in 1998 and is currently a member of their Board. He is a member
of the Medical Advisory Board of both the New Jersey Breast Cancer Coalition and Susan G. Komen Foundation and is an active member on
Scientific Advisory Boards of several universities. He served on various committees for the American Association for Cancer Research (Chair,
Clinical Cancer Research Committee), American Society of Clinical Oncology, the Association of American Cancer Institutes (Board of Directors),
and the National Cancer Institute Board of Scientific Advisors. Dr. Hait served as President of the American Association for Cancer Research
from 2007 - 2008.
Back to Top
Margaret Hamburg, MD, FDA Commissioner
Margaret Hamburg, MD, was confirmed on May 18, 2009 by a unanimous Senate voice vote to become the 21st Food and Drug Commissioner. The second woman to be nominated for that demanding position, Dr. Hamburg is exceptionally qualified for her new job by her training and experience as a medical doctor, scientist and public health executive.
Dr. Hamburg graduated from Harvard Medical School, and completed her residency in internal medicine at what is now New York Presbyterian Hospital-Weill Cornell Medical Center, one of the top-ten hospitals in the nation. She conducted research on neuroscience at Rockefeller University in New York, studied neuropharmacology at the National Institute of Mental Health on the NIH campus in Bethesda, and later focused on AIDS research as Assistant Director of the National Institute of Allergy and Infectious Diseases.
In 1990, Dr. Hamburg joined the New York City Department of Health and Mental Hygiene as Deputy Health Commissioner, and within a year was promoted to Commissioner, a position she held until 1997. During her tenure she was widely praised for her initiatives, decisive leadership, and significant public health measures she carried out despite severe budget constraints and while holding academic positions at Columbia University School of Public Health and Cornell University Medical College.
Dr. Hamburg's accomplishments as New York's top public health official included improved services for women and children, a needle-exchange program to reduce the spread of HIV, and the initiation of the first public health bio-terrorism defense program in the nation. Her most celebrated achievement, however, was curbing the spread of tuberculosis. In the 1990s, TB resurged as a major public health threat, largely because many patients did not complete the full course of the treatment and the disease became resistant to standard drugs. Dr. Hamburg confronted the problem by sending health care workers to patients' homes and taking other steps to make sure they completed the drug regimen. Thanks to this program, in a 5 year span, the TB rate in New York City fell by 46% overall, and 86% for the most drugresistant strains. Dr. Hamburg's innovative approach has become a model for health departments world-wide.
In 1994, Dr. Hamburg was elected to the membership in the Institute of Medicine, one of the youngest persons to be so honored. three years later, at the request of President Clinton, she accepted the position of Assistant Secretary for Policy and Evaluation in the U.S. Department of Health and Human Services (HHS).
In 2001, Dr. Hamburg became Vice President for Biological Programs at the Nuclear Threat Initiative, a foundation dedicated to reducing the threat to public safety from nuclear, chemical, and biological weapons. In that position, she has advocated broad reforms in public health infrastructure and policy, from local health departments to the national agency, in order to meet the dangers of modern bioterrorism as well as the threats of naturally occurring infectious diseases such as pandemic flu. Since 2005, Dr. Hamburg has served as the Initiative's Senior Scientist. President Barack Obama nominated her for the FDA Commissioner on March 25, 2009.
Upon Dr. Hamburg's confirmation by the U.S. Senate, HHS
Secretary Kathleen Sebelius has praised her as "an inspiring
public health leader with broad experience in infectious disease,
bioterrorism, and health policy", and added that "Personally, I
have been impressed by the calm and confidence Dr. Hamburg
has shown in the face of a wide variety of challenges."
Back to Top
Fred Hassan, Schering-Plough
Fred Hassan is chairman of the board and chief executive officer of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003 and assuming his current position, Hassan was chairman and chief executive officer of Pharmacia Corporation. He joined the former Pharmacia & Upjohn in May 1997 as chief executive officer and was elected to the Board of Directors. In February 2001, Hassan was named chairman of the Board of Pharmacia, the company created through the merger of the former Monsanto and Pharmacia & Upjohn companies.
Previously, Hassan was executive vice president of Wyeth, formerly known as American Home Products, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth's Board of Directors in 1995. Earlier in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business.
Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School.
Hassan is the past chairman of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and is the immediate past chairman of the HealthCare Institute of New Jersey. He is currently president of the International Federation of Pharmaceutical Manufacturers Associations. In addition, he serves on the Board of Directors of Avon Products, Inc.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and
collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its
research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to
"Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company
is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
Back to Top
Robert Langreth, Forbes
Robert Langreth has been a Senior Editor at Forbes since May 2000. He covers the drug industry, stem cell research, biotechnology, genetic engineering, neuroscience, genomics and gene therapy.
Before joining Forbes, Mr. Langreth was a Staff Reporter at the Wall Street Journal from 1995 to 2000 and an Associate Editor at Popular Science from 1992 to 1994. He is the recipient of several journalism awards, including a 1993 Evert Clark Award for Best Science Writing and a 1998 Council for the Advancement of Science Writing (CASW) Award. He was the co-recipient of a 1997 Polk Award.
Mr. Langreth graduated from Yale University in 1990 with a BA
degree in Physics and Philosophy.
Back to Top
Debra Lappin, Council for American Medical Innovation
Debra Lappin is recognized across government, academic and non-profit sectors as a public servant and leading strategist in public health and science policy. She serves as president to the Council for American Medical Innovation, an organization that brings together leaders in research, medicine, public health, academia, education, labor and business who are working in partnership toward a national policy agenda that preserves U.S. leadership in medical innovation.
As a senior vice president at B&D Consulting, Debra consults on innovative public-private partnerships and other alliances to drive translation research and public health promotion and prevention. Calling upon her experiences as former national chair of the Arthritis Foundation, she is a recognized national spokesperson on public engagement in the nation's public health and scientific enterprise.
Debra's practice focuses on the increasingly influential role of non-profit patient organizations as partners with government in research, development and prevention, where she orchestrates coalitions, global consortia, and other strategic alliances among academic research institutions, voluntary health agencies, government and industry. Areas of focus for such collaborative agreements have included work with the leading causes of disability, Arthritis and Alzheimer's disease, and rare diseases, such as Duchenne muscular dystrophy. Most recently, she has orchestrated science policy campaigns on issues of open access and genetic non-discrimination.
Drawing upon her understanding of health agency trends, law, ethics, and practical business challenges, she advises on the development of a broad range of emerging, complex tools to enable translation, such as disease registries, large integrated databases, bio-specimen repositories and cross-institution affiliations to share data.
Debra serves or has served as an advisor to the leading agencies in public health, including the Centers for Disease Control and Prevention and the
National Institutes of Health, and has participated on a number of committees at the National Academy of Sciences, including the Committee on the Organizational
Structure of the NIH which led to a number of directions incorporated in the 2006 NIH Reform Act. She is a member of the board of Research!America and
is a adjunct professor at the University of Colorado Health Sciences Center.
Back to Top
Roger Longman, Pharma, Elsevier Business Intelligence
Roger Longman is a Managing Director,
Pharma at Elsevier Business Intellegence, a
Reed Elsevier company. In 1983, Longman
joined The Wilkerson Group as a writer
covering the pharmaceutical and biotech industries for IN VIVO:
The Business & Medicine Report. In 1989, along with David
Cassak, he led a buyout of IN VIVO, moved the newly created
company-Windhover Information--to Connecticut. In addition to
IN VIVO, Windhover now publishes Start-Up, The RPM Report,
Medtech Insight, and The Strategic Transactions Database;
produces a series of in-depth market reports on the device
industry; and organizes a number of conferences, including
Pharmaceutical Strategic Alliances and The FDA/CMS Summit.
In 2004, Windhover acquired Medtech Insight, an information
company covering the medical device field through a marketleading
newsletter, a series of in-depth market reports, and
a number of conferences. In 2008, Windhover was acquired
by Reed Elsevier and merged with its FDC Reports division
(publishers of The Pink Sheet, The Tan Sheet and many other
medical-industry newsletters), creating Elsevier Business
Intelligence. Over the years, Mr. Longman has become recognized
as one of the leading experts in biopharmaceutical strategy and
dealmaking. He is often asked to speak at many key industry
events organized by important trade organizations like the
Biotechnology Industry Organization (BIO), investment banks,
venture capital firms and leading pharma and biotech companies.
He lectures regularly at several leading universities. Mr. Longman
completed his BA at Cornell University and an MA in English
literature at the University of North Carolina at Chapel Hill.
Back to Top
Greg Lucier, Life Technologies
Gregory T. Lucier serves as Chief Executive Officer of Life Technologies and as Chairman of the Company's Board of Directors. Previously, he served as Chairman and Chief Executive Officer of Invitrogen Corporation, which merged with Applied Biosystems in November 2008 to form Life Technologies. The Company is one of the largest providers of systems, biological reagents, and services, supplying scientists around the world in every way that life science technologies are applied. The company aims to improve the human condition by enabling basic research, accelerating drug discovery and development, and advancing scientific exploration in areas such as regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Mr. Lucier has leveraged his background in healthcare management to prepare the company to participate in and shape the new era of personalized medicine.
Mr. Lucier serves on the BIO Board of Directors as well as on the board of the Burnham Institute of Medical Research. He is actively involved
at San Diego State University as a distinguished lecturer. He received his B.S. in Engineering from Pennsylvania State University and an M.B.A.
from Harvard Business School.
Back to Top
Ven Manda, Medtronic
Ven Manda assumed the role of Vice President Medtronic Ventures and New Therapies in February 2009. In this role, Ven serves as the strategic leader for Medtronic venture programs, including enterprise-wide and whitespace opportunities focused on driving new growth. Ven also oversees the Medtronic Venture Fund and leads the Medtronic Strategy and Innovation (MSI) Venture team in efforts to identify, analyze, develop, and launch new technology and therapy opportunities. Additionally, in partnering with Medtronic Medicine and Technology, Business Development and Legal, he gains access to external technologies and partnerships that complement internal MSI venture program offerings.
Previously Ven served as Vice President of New Therapies & Diagnostics in CRDM. He joined Medtronic in 1994 as a Clinical Outcomes Manager in the Tachyarrhythmia division. In the last 15 years, he has held various positions in CRDM leading the clinical research in Atrial Fibrillation devices and subsequently was responsible for leading the Cardiac Resynchronization Program by guiding Medtronic's pivotal CRT-devices and trials through FDA panels
Ven has a master of science in economics and statistics from
Madras University and a bachelor of science in biology and
physiology from Andhra University. Ven was a recipient of the
prestigious Medtronic Wallin Leadership Award in 2002.
Back to Top
Edward McCabe, MD, PhD, American Society of Human Genomics
Edward McCabe, MD, PhD, is Professor in the Departments of Pediatrics and Human Genetics, and Mattel Endowed Executive Chair of the Department of Pediatrics, David Geffen School of Medicine at UCLA, and Physician-in-Chief of the Mattel Children's Hospital at UCLA. He is Professor of Bioengineering, Herny Samueli School of Engineering, UCLA and Member, California Nanosystems Institute. He directs the Pediatric Research, Innovation and Mentoring Experience (PRIME) Program, the UCLA Child Health Research Career Development Award, the Human and Molecular Development Postdoctoral Training Program, and the UCLA International Pediatric Education, Training, and Translation (IPERT) Program. He founded and serves as Co-Director of the UCLA Center for Society and Genetics. He recently established the first program in NanoPediatrics.
A pediatrician and geneticist, Dr. McCabe began his research career at the age of 15 in the Pediatric Research Laboratory at the University of Maryland, School of Medicine. He received his B.A. from The Johns Hopkins University (1967), and his PhD (1972) and MD (1974) from the University of Southern California. He completed his Pediatrics Residency at the University of Minnesota (1974-1976). At the University of Colorado Health Sciences Center, he was a Pediatric Metabolism Fellow (1976- 1978) and then Assistant and Associate Professor of Pediatrics, and Biochemistry, Biophysics and Genetics. In 1986 he moved to Baylor College of Medicine as Associate Professor then Professor, and Director of the Robert Kleberg Jr. Clinical Center in the Institute for Molecular Genetics. He established the Baylor Mental Retardation Research Center, the Baylor Molecular Genetics Diagnostic Laboratory Postdoctoral Training Program, and the Baylor Child Health Research Center.
Dr. McCabe identified the first patients with Glycerol Kinase Deficiency, part of a contiguous gene syndrome with Adrenal Hypoplasia Congenita and Duchenne Muscular Dystrophy. He cloned the genes for Glycerol Kinase Deficiency and Adrenal Hypoplasia Congenita, and continues to study the systems biology of these disorders. He was the first to show that DNA could be extracted from newborn screening blotters. This discovery is the basis for the use of blotters for molecular genetic diagnosis, forensics (including the DNA dog tag) and infectious disease diagnosis.
He and Linda McCabe, PhD, wrote How to Succeed in Academics
(Academic Press, 2000). The second edition will be published by
the University of California Press in February 2010. They also
wrote DNA: Promise and Peril (University of California Press,
2008) to support their course for 120 UCLA undergraduates.
They are currently expanding this curriculum for team teaching
by a Biology teacher and a History teacher at the King Drew
Medical Magnet High School (LAUSD).
Back to Top
Thomas Miller, Jr., Workflow & Solutions Division,
Thomas Miller, Jr. is Chief Executive Officer of Siemens Healthcare's Workflow and Solutions division. Previously, Tom was a member of the Group Board of Siemens Medical Solutions and has an impressive record of leadership within Siemens and other multi-national companies. He served as President and Chief Executive Officer, of Health Services, Siemens Healthcare Information Technology business, and has led the magnetic resonance division and the U.S. sales and service organization.
Additionally, he was president and Chief Executive Officer of Carl Zeiss, Inc., the American subsidiary of the multi-billion dollar optical company and simultaneously the general manager of the worldwide medical division of Carl Zeiss, responsible for surgical microscopes and ophthalmology products. Tom also served as President and Chief Executive Officer of Analogic Corporation, a manufacturer of components and subsystems for the healthcare and security industry. He co-founded a company, LightLab Imaging, to commercialize a new diagnostic imaging method called optical coherence tomography (OCT) enabling the acquisition and display of real-time ultra high-resolution cross sectional images with light.
This broad range of experience and expertise in medical physics and information technology have served to shape Tom's passion for medicine and for transforming how we approach the prediction, prevention, diagnosis, and treatment of disease.
Tom holds a BS in Nuclear Engineering with a minor in English
Literature from the University of Massachusetts and a Masters of
Science degree from the Harvard Medical School/Massachusetts
Institute of Technology (MIT) joint program in Medical Physics.
Back to Top
David Nexon, AdvaMed
David Nexon is Senior Executive Vice
President of the Advanced Medical
Technology Association ("AdvaMed"), where
he is responsible for domestic policy. Prior to
joining AdvaMed, Mr. Nexon served for more than twenty years
as the Democratic Health Policy Staff Director for the Senate's
Health, Education, Labor and Pensions Committee and as the
Senior Health Policy Advisor to Senator Edward M. Kennedy. In
these capacities, he has been involved with most of the major
health policy issues of the last two decades. Prior to joining
Senator Kennedy's staff, Mr. Nexon was Senior Budget Examiner
in the Health Branch of the Office of Management and Budget,
where he was responsible for the Health Care Financing
Administration (now the Center for Medicare and Medicaid
Services). Mr. Nexon held several academic appointments prior
to entering government service. He received his BA from Harvard
College and his PhD from the University of Chicago.
Back to Top
Sam Palmisano, IBM
Sam Palmisano is Chairman of the Board, President and Chief Executive Officer of the IBM Corporation. Mr. Palmisano was appointed to this position on January 6, 2003. Previously, he served as President and Chief Operating Officer.
He began his career in 1973 in Baltimore, Maryland. Since then, Mr. Palmisano has held a series of leadership positions during his IBM career, including senior vice president for the Enterprise Systems and Personal Systems groups. Mr. Palmisano also played a key role in creating and leading IBM's Global Services, rising to senior vice president, and building the largest and most diversified IT services organization in the industry. He also served as senior managing director of operations for IBM Japan.
Mr. Palmisano is a graduate of The Johns Hopkins University. In recognition of his leadership role as co-chair of the Council of
Competitiveness' National Innovation Initiative, as well as his many business accomplishments, Mr. Palmisano was awarded an Honorary
Degree of Doctor of Humane Letters from Rensselaer Polytechnic Institute in September 2005. In July 2006, he was awarded an Honorary
Fellowship from the London Business School.
Back to Top
Sir Bruce Ponder, MD, PhD, Cancer Research UK
Cambridge Research Institute
Bruce Ponder is Li Ka Shing Professor of Oncology at Cambridge and Director of the Cancer Research UK Cambridge Research Institute, and Co-Director of the Hutchison/MRC Research Centre and of the Strangeways Research Laboratory for Genetic Epidemiology. His interests are in inherited susceptibility to cancer, and in the effective application of basic science to cancer treatment, detection and prevention.
He trained in medicine in London and then did a PhD at ICRF in molecular biology. He trained in medical oncology at the Dana Farber Cancer Institute, Harvard Medical School. Subsequently during a Cancer Research Campaign Career Development Award he developed new methods to reveal the mosaicism in tissues of chimeric mice, with the aim of understanding the normal clonal cellular organisation of tissues, and how this breaks down in cancer. He also provided some of the first data on the stem cell organisation of the new intestinal crypt, showing (among other things) that intestinal crypts are clones.
During this time he developed a clinical interest in cancer genetics, establishing one of the first clinics for familial cancer. His laboratory identified ret as the gene for MEN 2 syndrome, and he was the first Chair of the International Consortium which ultimately underpinned the finding of the BRCA1 and BRCA2 genes. His research efforts are now focussed on common genetic variation and susceptibility to cancer, and his group recently completed the first successful genome scan for breast cancer, which has identified 7 new loci for predisposition. They have also demonstrated the potential application of this information to targeting screening and prevention.
Over the past 10 years Bruce Ponder has led the development of a new laboratory and clinical centre for cancer research in Cambridge, culminating
in 2007 with the opening of the new CRUK Cambridge Research Institute. He was knighted in 2008 for services to medicine.
Back to Top
Tomas Puusepp, Elekta
Tomas Puusepp has served as President and CEO of Elekta since 1 May, 2005. Born 1955, he has total of 27 year of experience in the international
medical technology market. Following studies in engineering and physics and management training at IMD in Lausanne, Switzerland, Tomas Puusepp held
various positions at the Research Institute for Nuclear Physics, Scanditronix and Ericsson before being employed by Elekta in 1988. Since then, he
has held various management positions within the company, including head of Elekta's neurosurgery operations, President of Elekta's subsidiary in
North America and global head of Elekta's sales, marketing and service operations. Tomas Puusepp is a member of the Board of Bactiguard AB.
Back to Top
Harry Rein, Foundation Medical Partners
Mr. Rein is General Partner of Foundation Medical Partners. He served for 15 years as the Founder and Managing General Partner of Canaan Partners. In addition to his role as the Managing General Partner at Canaan Partners, Mr. Rein was responsible for Canaan's Life Sciences Investment Practice. Prior to Canaan Partners, he was President and Chief Executive Officer of GE Venture Capital Corporation. Mr. Rein has extensive experience with small and mid-sized companies, including the supervision of all investments made by GE Venture Capital during his tenure as President. Mr. Rein joined the General Electric Company in 1979 and directed several of GE's lighting businesses as general manager before joining the venture capital subsidiary. He has also worked for Transaction Systems, a strategic consulting firm, as a Vice President; with Gulf Oil Corporation as Director of Corporate Planning; and with Polaroid Corporation in several manufacturing positions. Mr. Rein has served on the boards of directors of more than 20 public and private entrepreneurial companies, including: Cell Pathways, OraPharma (acquired by Johnson & Johnson), National MD (acquired by GE), OmniSonics, GenVec (NASDAQ: GNVC), CardioNet (NASDAQ: BEAT) and Spine Wave, and was an investor in Praecis Pharmaceuticals (NASDAQ: PRCS). Currently, Mr. Rein serves on the Board of Directors of Anadigics (NASDAQ: ANAD), CardioNet (NASDAQ: BEAT) and Spine Wave. Previously, Mr. Rein was a member of the Board of Directors of the National Venture Capital Association ("NVCA") and was a recipient of the 2002 NVCA Outstanding Service Award. Mr. Rein also serves as a Trustee of Cleveland Clinic, and is a member of the Clinic's Research and Education, Finance and Budgeting, and International and Emerging Opportunities committees. Mr. Rein is Chairman of the Cleveland Clinic Industrial Advisory Board. He also serves as a Trustee of the University of Virginia Darden School of Business Foundation, where he is a member of the Executive Committee and Chairman of the Investment Committee.
Mr. Rein attended Emory University and Oglethorpe College
(1968) and holds an MBA from the Darden School at the
University of Virginia (1973).
Back to Top
Wayne A. Rosenkrans, Jr., PhD, MIT Center for
Wayne is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy
issues related to science and medicine, a member of the Ethics and Systems Medicine Program at Georgetown University and Chairman
& President of the board of directors of the Personalized Medicine Coalition, a Washington DC based organization working with
government and other agencies on evolving healthcare policy for Personalized Healthcare. He is also VP Strategic Consulting at
Fuld and Co focusing on strategic simulations in healthcare and Chief Applications Officer for SciTech Strategies focusing on
scientific competency and capacity development for academia and industry. He is a former Director of External Relations for
Personalized Healthcare and Evidence-based Medicine (EBM) as part of External Medical Relations at AstraZeneca where he had
responsibility for long-range external relations strategy and policy development. Prior to that role, he was involved in long-term
strategy development for the AstraZeneca Discovery, Development, and US Commercial divisions, and created and ran strategic intelligence
units at both AstraZeneca and SmithKIine Beecham Pharmaceuticals. He is a former President of SCIP and has received the SCIP Fellows
award and Lifetime Achievement Award in Intelligence from Frost and Sullivan. He has presented at numerous forums on aspects of
personalized healthcare, evidence-based medicine, new development paradigms, and strategy development. He holds an S.B. in Biology
from MIT, a Ph.D. in Cell and Molecular Biology from Boston Univ., and received post-doctoral training in Cancer and Radiation Biology
at the Univ. of Rochester. Wayne lives in Malvern, PA, is married with two college-age children, and enjoys teaching martial arts
(Tang Soo Do), restoring antique/classic Fords, and aviation history.
Back to Top
Richard Scheller, PhD, Genentech Research and
Richard Scheller is executive vice president, Research and Early Development. In this role, he is responsible for overseeing the strategy for Genentech's research, drug discovery, business development and early development activities (through proof of concept in the clinic). Scheller also serves on Genentech's Research Review Committee. Scheller is a member of Genentech's executive committee and the Enlarged Roche Corporate Executive Committee.
Scheller joined Genentech in 2001 as senior vice president, Research and was promoted to executive vice president, Research in 2003 and appointed chief scientific officer in June 2008. He assumed his current role in May 2009.
Prior to joining Genentech, Scheller was appointed to the esteemed position of professor of Molecular and Cellular Physiology and Biological Sciences in 1993 and as an investigator with the Howard Hughes Medical Institute in 1994. Scheller received his first academic appointment to Stanford University in 1982.
Scheller's work has earned him numerous awards, including the 1997 National Academy of Sciences Award in Molecular Biology. He is a member of the Academy of Arts and Sciences and the National Academy of Sciences, and has served on numerous advisory boards, including the National Advisory Mental Health Council of the National Institutes of Health. He has published more than 200 papers in peer-reviewed scientific journals.
Scheller received his Bachelor of Science in biochemistry at the University of Wisconsin, Madison and was awarded his doctorate in chemistry from
the California Institute of Technology, where he was also a postdoctoral fellow, Division of Biology. Scheller was also a postdoctoral fellow at
Columbia University, College of Physicians & Surgeons.
Back to Top
Richard Schilsky, MD, American Society of Clinical Oncology
Dr. Schilsky earned his M.D. at the University of Chicago Pritzker School of Medicine in 1975. Following a residency in Internal Medicine at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital, he received training in Medical Oncology and Clinical Pharmacology at the National Cancer Institute from 1977 to 1981. He then served as Assistant Professor of Medicine at the University of Missouri-Columbia School of Medicine from 1981-1984 when he returned to the University of Chicago where he is presently Professor of Medicine (tenured). At the University of Chicago, Dr. Schilsky has served as Director of the University of Chicago Cancer Research Center (1991-99) and as Associate Dean for Clinical Research (1999-2007). Since 1995, Dr. Schilsky has served as Chairman of the Cancer and Leukemia Group B.
An international expert in gastrointestinal malignancies and cancer pharmacology, he has served on a number of peer review and advisory committees for the NCI and previously served as Chair of the Oncologic Drugs Advisory Committee for the FDA. Dr. Schilsky currently serves as a member of the NCI Board of Scientific Advisors and the Clinical Trials Advisory Committee. He previously served as a member of the NCI Clinical Trials Working Group and the Translational Research Working Group. Dr. Schilsky has served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and is presently the Immediate Past President of ASCO.
He is a member of the external advisory committees of several comprehensive cancer centers including the Roswell Park Cancer Center, the Mayo Cancer Center, the MD Anderson Cancer Center and the Fred Hutchinson Cancer Research Center. He has also served as a member of the Selection Committee for the Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research.
Dr. Schilsky is an Associate Editor of Clinical Cancer Research and Cancer and a member of the editorial board of Seminars in Oncology, the Journal of
Cancer Research and Clinical Oncology and several other journals. He has published more than 250 articles and book chapters in the medical literature and
is the editor of 4 books.
Back to Top
Steve Schimoler, Crop, Bistro & Bar
Inventor, entrepreneur, and self-taught chef, Steve Schimoler's career has taken him from Long Island to the Lake Erie shore, always in pursuit of new challenges. At 23, Steve launched his first Long Island restaurant; within three years, he had three businesses running simultaneously, including Loafers Bakery and Gourmet, The Terrace Too and his flagship restaurant The Black Walnut which received 3 stars from New York Newsday critics, and positioned Schimoler as one of New York's top toques.
Yet in 1990 Schimoler sold everything and headed to Vermont to become VP of product development for Cabot Creamery. Schimoler had invented a process that incorporated liquids into butter and in no time truck loads of intensely flavored butters were being sold across the nation. Then, an accidental discovery led to an invention of a new product (still available today under the name Culinary Cream) which Schimoler sold to the NutraSweet Company. That, in turn, prompted him to start a Product Development Firm called Right Stuff.
Right Stuff led to a company called Chef Stuff, which found Steve and his chef colleagues (including Todd English, Rick Bayless, David Burke, Douglas Rodriquez, and Nancy Silverton) creating signature menu items that were produced in a state of the art manufacturing facility which Steve designed and built. Steve's desire to connect chefs with small regional, artisan producers led to yet another business, Chefex.com, which utilized the nascent power of the internet to distribute artisan ingredients nationally using service partners AMEX and FEDEX.M
In 1999, Steve went on to restore a 200-year old grist mill in Vermont and reopen it as The Mist Grill, a cozy haven that immediately earned national acclaim for its inventive, rustic cuisine. (Steve's cookbook, The Mist Grill: Rustic Cooking from Vermont, still is available in bookstores and on Amazon.com.)
Steve relocated to Cleveland in 2005, as Director of Innovation
and Development for Nestle North America and, after completing
his term there, decided to remain in Cleveland. His current
restaurant venture, Crop Bistro & Bar, opened in the Historic
Warehouse District in June 2007. While Crop was initially
imagined as Steve's test kitchen (the name is an acronym for
Customized Restaurant Operations Platform), it quickly grew
into one of Cleveland's premier lunch and dinner destinations,
attracting both critical acclaim and a cadre of devoted diners,
drawn to Steve's unique blend of culinary artistry, whimsy, and
Back to Top
Randy Scott, PhD, genomic health, inc.
Randy Scott, Ph.D. has served as Executive Chairman since January 2009. Prior to serving as Chairman, Randy served as Chairman and
Chief Executive Officer from August 2000 through January 2009. Randy was a founder of Incyte Corporation, a genomic information company,
and served Incyte in various roles, including Chairman of the Board from August 2000 to December 2001, President from January 1997 to
August 2000 and Chief Scientific Officer from March 1995 to August 2000. Randy holds a Bachelor of Science degree in Chemistry from
Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
Back to Top
Beth Seidenberg, MD, Kleiner Perkins Caufield & Byers
Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in the life sciences area. For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer, psoriasis, cardiovascular, metabolic, neurological and renal disorders. She introduced 10 innovative products to market and achieved more than 40 regulatory approvals (including new indications and formulations) on a worldwide basis. These products have been successfully commercialized and have generated several billion dollars of revenue.
Prior to joining KPCB, Beth was Senior Vice President, Global Development, and Chief Medical Officer at Amgen, Inc., the world's largest biotechnology company. During Beth's three years there, her responsibilities included: all stages of clinical research, regulatory affairs, safety, health economics/reimbursement and medical affairs. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases.
Beth received her BS from Barnard College magna cum laude, Phi
Beta Kappa; and her medical degree from the University Of Miami
School Of Medicine, alpha omega alpha. Her post-graduate
training was completed at Johns Hopkins, George Washington
School of Medicine and the National Institutes of Health.
Back to Top
Nancy Simonian, MD, Millennium: Takeda Oncology Co.
Dr. Simonian is the Chief Medical Officer at Millennium, The Takeda Oncology Company which is focused on innovative cancer medicines. She is responsible for Clinical Development, Regulatory Affairs, Pharmacovigilance, and Development Project and Portfolio Management. Dr. Simonian is a member of the executive management team of Millennium and chairs the company's Portfolio Review Committee. She is a member of the board of Arqule Pharmaceuticals, Inc. and the Personalized Medicine Coalition.
Prior to joining Millennium, Dr. Simonian was a Vice President of Clinical Research at Biogen where she was responsible for the clinical development of AVONEX® (Interferon beta-1a), Tysabri (natalizumab), and their oncology programs.
She is a graduate of Princeton University and received her M.D. from the University of Pennsylvania School of Medicine. She did
her internship in medicine and residency in neurology at the Massachusetts General Hospital (MGH) and was an Assistant Clinical Professor
at MGH and at Harvard Medical School prior to joining industry.
Back to Top
Richard Smith, PhRMA
Richard Smith is the Senior Vice President for Policy, Research and Strategic Planning at the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Smith works to advance policies that encourage medical progress and patient access to the fruits of pharmaceutical innovation.
Previously, Mr. Smith was Vice President, Public Policy and Research at the American Association of Health Plans; Vice President, Health Policy at the Association of Private Pension and Welfare Plans (now the American Benefits Council); Director, Public Policy at the Washington Business Group on Health; and Staff Director of the Maryland Governor's Commission on Health Care Policy and Financing.
Mr. Smith is the principal author of two chapters of The Managed Health Care Handbook, 4th edition (2000), which is the premier reference on managed care practices. He also has written on disease management in The American Journal of Managed Care (forthcoming), the Health Insurance Portability and Accountability Act in the Benefits Law Journal (1996), and defense procurement policy in International Security (1982).
Mr. Smith holds a JD from the University of Maryland, an MA in Political Science from Johns Hopkins University and a BA from Wesleyan University. He resides in Columbia, Maryland with his wife and three sons.
PhRMA represents the country's leading research-based
pharmaceutical and biotechnology companies, which are
devoted to inventing medicines that allow patients to live longer,
healthier, and more productive lives.
Back to Top
Kári Stefánsson, MD, deCode
Kári Stefánsson, M.D., Dr. Med. has served as President, Chief Executive Officer and a Director since he co-founded deCODE in August
1996. Dr. Stefánsson was appointed to serve as the Chairman of the Board of Directors in December 1999. From 1993 until April 1997, Dr.
Stefánsson was a professor of Neurology, Neuropathology and Neuroscience at Harvard University. In addition, from 1993 through December
1996 he was Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. From 1983 to 1993, he held faculty positions in
Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University
of Iceland and is board-certified in neurology and neuropathology in the United States.
Back to Top
Dietrich Stephan, PhD, Navigenics
Dr. Stephan is a human geneticist who works to understand the root causes of common human diseases so that early diagnostics and interventions can be implemented. Dr. Stephan most recently was the deputy director of discovery research at the Translational Genomics Research Institute and still holds a faculty appointment there. Dr. Stephan has identified genes that predispose to disorders such as autism, exercise-induced heart attacks and sudden infant death syndrome, and contributed to understanding a multitude of common "complex genetic" disorders such as Alzheimer's disease.
Dr. Stephan is chairman of the National Institutes of Health (NIH) Neuroscience Microarray Consortium, and has previously held faculty
appointments at Johns Hopkins University, the National Human Genome Research Institute of the NIH, the University of Arizona, Arizona State
University, George Washington University and the Children's National Medical Center in Washington, D.C. Dr. Stephan has published extensively
in journals such as Science, the Proceedings of the National Academy of Sciences, Nature Genetics and the New England Journal of Medicine. Dr.
Stephan received his B.S. at Carnegie-Mellon University and his Ph.D. at the University of Pittsburgh, and trained as a fellow at the National
Human Genome Research Institute of the NIH.
Back to Top
Euan Thomson, PhD, Accuray, Inc.
Euan Thomson, PhD has served as Chief
Executive Officer and a member of Accuray's
Board of directors since March 2002 and as
President since October 2002. From March
1999 to February 2002, Dr. Thomson served during various
periods as President, Chief Executive Officer and a member of
the Board of Directors of Photoelectron Corporation, a publicly
held medical device company. Prior to joining Photoelectron,
Dr. Thomson held various positions as a medical physicist within
the United Kingdom National Health Service and worked as
a consultant for medical device companies, including Varian
Oncology Systems and Radionics, Inc. Dr. Thomson holds a BS
in Physics, an MS in Radiation Physics and a PhD in Physics,
with an emphasis on stereotactic brain radiotherapy, each from
the University of London.
Back to Top
Mark Trusheim, Co-Bio Consulting
Mark Trusheim is a Visiting Scientist and Executive-In-Residence at the MIT Sloan School of Management. He has been a Special Government Employee for the FDA's Office of the Commissioner and is the Founder and President of Co-Bio Consulting, LLC. He holds degrees in Chemistry from Stanford University and Management from MIT. Mark's research focuses on modeling the introduction of new innovations in healthcare, such as stratified medicines, to inform public policy, corporate strategy and product development programs.
He is a MBC member of the Massachusetts Biotechnology Council's Board of Directors, which helps its over 500 members succeed in the state. In 2004 he further served as the Interim President of the MBC, leading its successful legislative agenda, its expansion of MassBioEd education programs and its continued membership growth.
Co-Bio Consulting focuses on biotechnology public policy, corporate development and regional biotech cluster development. Clients include established biopharma firms, start-up biotechs, universities and government agencies.
As an entrepreneur, Mark founded and was the first President and Chief Executive Officer of Cantata Laboratories. Cantata marketed clinical diagnostics and pharmaceutical biomarker services based on its biochemical profiling platform.
Prior to Cantata, Mark worked at Monsanto/Pharmacia, culminating his career there as Co-President and Chief Operating Officer of Cereon Genomics, LLC. Located in Cambridge, Massachusetts, Cereon was created in 1997 by Monsanto as part of a $500 million collaboration with Millennium Pharmaceuticals. Prior to his position at Cereon, Mark was responsible for Monsanto's external genomics relationships and held roles of Vice President in the Health and Wellness Sector, Marketing Director in Searle Pharmaceutical and Director in Agriculture Division Strategy.
Mark spent the first half of his career in the high tech industry
working at Wang Laboratories in computer hardware and at Kenan
Systems Corporation, later acquired by Lucent for $1.4 billion,
which developed quantitative models and artificial intelligence
applications for large corporations and government agencies.
Back to Top
Mark Vachon, GE Healthcare
As President & CEO of GE Healthcare's $9 billion Americas Region and as a GE Corporate Officer, Mark L. Vachon leads GE Healthcare's activities in the United States, Canada and Latin America. With responsibilities spanning across all of GE Healthcare's diagnostics, health information technology and life sciences product and service offerings, Mark's primary focus is on leveraging the capabilities of GE Healthcare in partnering with governments and healthcare providers to improve access, quality and costs.
Most recently, Mark served as President and CEO of GE Healthcare's $8 billion Global Diagnostic Imaging organization headquartered in Waukesha, Wisconsin, providing world-class technology in imaging and diagnostics.
Since joining GE in 1982, and graduating GE's leadership programs, Mark has provided leadership in a number of GE's businesses, including the Global Research Center, GE Appliances, GE Plastics (recently sold to Saudi Basic Industries Corp), NBC, and GE's investor relations. In recognition for his contribution to GE, Mark was appointed a Corporate Officer in 1999.
Mark is an active member of the Center for Corporate Innovation and the Metropolitan Milwaukee Association of Commerce. He is a Board member
of the Imaging Sector of the Advanced Medical Technology Association. Mark also serves on the Overseers Board for Northeastern University,
Boston, his alma mater.
Back to Top
Daniel Vasella, MD, Novartis
Daniel Vasella, MD, is Chairman and Chief
Executive Officer of Novartis AG. He was
appointed Chairman in April 1999, having
served as Chief Executive Officer and
executive member of the Board of Directors since the merger
that created Novartis in 1996. Before the Novartis merger,
Dr. Vasella was Chief Executive Officer of Sandoz Pharma Ltd.
and a member of the Sandoz Group Executive Committee.
From 1988 to 1992, he was with Sandoz Pharmaceuticals
Corporation in the US, prior to which he held a number of
medical positions in Switzerland. He graduated with an MD
from the University of Bern and completed executive training
at the Harvard Business School. He was also awarded an
honorary doctorate by the University of Basel. Dr. Vasella is
a member of the Board of Directors of PepsiCo, Inc. and the
Board of Alcon. He is also a member of the International
Board of Governors of the Peres Center for Peace in Israel, the
International Business Leaders Advisory Council for the Mayor
of Shanghai, the Global Health Program Advisory Panel of the
Bill & Melinda Gates Foundation and is a foreign honorary
member of the American Academy of Arts and Sciences.
In addition, he serves as a member of several industry
associations and educational institutions.
Back to Top
Jon Wigginton, MD, Bristol-Myers Squibb, Inc.
Dr. Wigginton earned his M.D. at the University of Michigan Medical School in 1989. After completing a combined internship in medicine-pediatrics and a residency in pediatrics at the University of Michigan Hospitals, he completed fellowship training in pediatric hematology-oncology in 1995 at the Pediatric Oncology Branch, Center for Cancer Research, NCI. Dr. Wigginton subsequently joined the NCI as a principal investigator, serving as Head of the Investigational Biologics Section, NCI. During this time, Dr. Wigginton established an international reputation as head of an integrated laboratory and early clinical research program focused on basic, preclinical and clinical investigation of novel combination strategies for the treatment of both pediatric and adult solid tumors. He has served on numerous committees and advisory boards focused on drug development, led several international scientific programs focused on tumor immunology and cancer immunotherapy, and is the Immediate Past-President of the International Society for the Biological Therapy of Cancer (iSBTc), the leading international translational research organization focused on tumor immunology and the immunotherapy of cancer. Dr. Wigginton has published widely and is a frequent speaker at national and international scientific programs.
Dr. Wigginton joined the pharmaceutical industry in 2006, initially at Merck Research Laboratories, and more recently at Bristol-Myers
Squibb, where he serves as Group Medical Director, Discovery Medicine-Clinical Oncology. During his industry tenure, Dr. Wigginton has
led numerous early and late clinical development teams and has overseen both clinical translation of several novel investigational
agents as well as the execution of global registrational trials.
Back to Top
Dow Wilson, Varian Medical Systems
Dow Wilson joined Varian Medical Systems in 2005, following a 19-year career with General Electric, in a variety of senior management
positions. Most recently, Wilson served as CEO for GE Healthcare-Information Technologies. Prior to that, he served as general manager
for a number of businesses, including, at different times, the X-ray, Functional Imaging, Computed Tomography (CT), and Positron Emission
Tomography businesses. A graduate of Brigham Young University, Wilson also holds an MBA from the Amos Tuck School of Business at Dartmouth
College. Wilson is also a director of Saba Software, Inc., a human capital management software provider.
Back to Top
Anne Wojcicki, 23 and Me
Anne brings to 23andMe a 10-year background in healthcare investing, focused primarily on biotechnology companies. Anne left the investing
world with the hope that she could have a positive impact on research and medicine through 23andMe. From her vantage point, Anne saw a need
for creating a way to generate more information - especially more personalized information - so that commercial and academic researchers could
better understand and develop new drugs and diagnostics. By encouraging individuals to access and learn about their own genetic information,
23andMe will create a common, standardized resource that has the potential to accelerate drug discovery and bring personalized medicine to the
public. (Plus, getting access to her own genetic information and understanding it has always been one of Anne's ambitions.) Anne graduated from
Yale University with a B.S. in biology.
Back to Top
Eric Ziebold, Mandarin Oriental
Eric Ziebold was named ‘Best Chef: Mid-Atlantic' at the James Beard Foundation Awards 2008. Chef Ziebold was one of ten chefs who received the prestigious James Beard ‘Best Chefs in America' title in 2008, displaying outstanding achievement in their region. This is the first time in Mandarin Oriental culinary history for a chef to receive this elite award. In addition to winning this prominent award, he was named "Chef of the Year" by the Restaurant Association of Metropolitan Washington, DC. He continues to demonstrate his rare talents at CityZen and maintains a creativity that has bestowed numerous accolades.
After eight years at The French Laundry in California, Ziebold left to open CityZen in Mandarin Oriental, Washington, DC. This was a step of personal success after an excellent career that began when he graduated with honors from the Culinary Institute of America.
His affinity for cooking started in his mother's kitchen growing up in Iowa. After graduation he gained his first position in Washington DC at Vidalia, from there he moved to Los Angeles as chef de partie at Spago Restaurant and then joined Thomas Keller with whom he worked with at The French Laundry and later assisted in the creation of Per Se in New York.
Chef Ziebold had established his own unique style of modern American cuisine. He brings his own interpretations and classic French style to
introduce new flavors. The result is specialties such as Pan Seared Valley Duck Breast with Fois Gras or Poached Maine Lobster with Roasted
Back to Top